Iambic IPO Valuation Beats Isomorphic

Iambic Therapeutics plans to go public this week with a target valuation of $900 million, raising around $160 million. This contrasts sharply with competitor Isomorphic Labs, which is in talks to raise funds at a valuation of at least $40 billion. The disconnect highlights investor preference for AI-first approaches over bio-first methods in drug discovery.